Nov. 8, 2018

This week the Food and Drug Administration has approved the product canagliflozin to reduce the risk of major adverse cardiovascular events, including heart attack, stroke or death due to a cardiovascular cause in adults with Type 2 diabetes who have established cardiovascular disease. Although we are all familiar with the cardiovascular benefits of the SGLT-2 Inhibitors, this is the first time the FDA has said that an SGLT-2 Inhibitor can reduce the risk.

The good things about this class of drugs continue to increase, as you can see in this month’s Therapy Edition.

Dave Joffe

Editor-in-chief